Clinical Trial

A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is being done to understand how much of the medicine (CDR132L) enters the bloodstream after injection under the skin compared to injection into a vein in healthy people. This will help us find the best way to give the medicine to people living with heart failure. The study will assess what the body does to the medicine, and how safe it is.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-01
critical Primary endpoint(s) modified 2026-07-01
Trial Details
NCT Number NCT07656454
Lead Sponsor Novo Nordisk A/S
Conditions Healthy Volunteers, Heart Failure
Enrollment 32 participants
Start Date 2026-06-17
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-30